NM CT 870 CZT

Bring theory to life with CZT

Introducing NM/CT 870 CZT, our third-generation, general purpose SPECT/CT system powered by CZT technology. It combines improvements in lesion detection¹, image quality and patient comfort with advanced quantitative applications provided through Xeleris™. This latest generation offers an all-new SmartConsole, new CT features, and the capability of imaging the higher energy peaks of medium energy isotopes. Help bring your theories to life with a system designed to leverage all that CZT can do for a wider variety of procedures.

CZT is the key component to the future of nuclear medicine. Not only is it lighter and more compact than the Nal crystals used in analog technology, it is pixelated. Each detector head consists of 130 CZT detector modules, which means there are tens of thousands of tiny 2.46 mm-sized pixels capturing events independently, all via direct conversion. With CZT and registered collimation, each photon is directly converted into an electrical signal that more accurately identifies its location and energy. This design reduces the signal loss and noise inherent in conventional SPECT detection by eliminating gamma photon conversion through scintillation and light conversion through PMT. The result is increased spatial and energy resolution.

NM/CT 870 CZT is the third-generation of our general purpose digital SPECT/CT system designed with this breakthrough CZT detection technology. An important capability unique to NM/CT 870 CZT is the ability to image low energy and medium energy isotopes with energies up to 250 keV. Accessibility to the Medium Energy High Resolution & Sensitivity (MEHRS) collimator, via collimator exchange, will expand your full-service SPECT/CT offering to include theranostics applications and potentially eliminate the need for a supplemental NaI-based SPECT system. Combined with the latest Xeleris quantitative applications and CT advancements that include a 32-slice overlapped reconstruction capability, the latest dose reduction technologies and Smart MAR, this system will transform your entire nuclear medicine experience.

• Up to 75 percent reduction in injected dose or scan time ²
• Improved system spatial resolution, from 4.3 mm to 2.8 mm ³
• Exceptional energy resolution, 6.3 percent compared to 9.5 percent
• Greater than 40 percent improvement in SPECT contrast-to-noise ratio ⁴
• 67 percent reduction in detector frame size, from 7.5 cm to 2.5 cm
• 25 percent greater optimal FOV than Nal
• 1.4 times higher count rates than conventional technology
• Up to 50 percent reduction in injected dose or scan time with Evolution technology ⁵
• Leverage advanced CT dose reduction technology with ASiR™ ^,6
• 7.25 mm thick CZT module for medium energy imaging
• Maintain quantitative SPECT accuracy when corrected by low-dose CT with Q.AC ^,7
• Up to a 2x increase in sensitivity for medium energy imaging ⁹
• Smart MAR helps reduce photon starvation, beam hardening and streak artifacts caused by metal in the body, such as hip implants
• Platform compatible with advanced digital solutions designed to connect machines, people and data throughout a portfolio of healthcare analytics applications

All our new 800 Series SPECT/CT systems build on the success of the 600 Series with a collection of SPECT technology enhancements that add to the value of nuclear medicine. The all-new SmartConsole provides enhanced workflow, increased accessibility and untethered clinical collaboration. Additionally, Step & Shoot Continuous SPECT acquisitions provide improved volume sensitivity compared to Step & Shoot acquisitions.

As molecular imaging continues to move toward the development of disease-specific diagnoses and increasingly personalized care, resolution is important. Early disease detection is only possible with a high system resolution that enables visualization of finer anatomic detail. In addition, research with multi-isotope exams requires precise energy resolution to reduce spillover between tracers. NM/CT 870 CZT has a 6.3 percent energy resolution and the ability to detect the energy from multiple tracers with more definition, making it possible to explore new protocols with the variety of SPECT tracers available.

With direct conversion detection, NM/CT 870 CZT has substantially improved system resolution by eliminating the signal loss and noise that comes with analog detection technology. It also uses a registered collimation design that aligns each collimator hole with a single detector pixel. This design eliminates the impact of collimator resolution that would normally affect the overall system resolution. The result is an improved contrast-to-noise ratio and spatial resolution down to 2.8 mm³

.

Just like the transition from analog to digital technology in other industries, the technology required to create a digital image is lighter, and more compact, with fewer constraints on system design. Using registered collimation, NM/CT 870 CZT contains detected events entirely within a single pixel aligned to one collimator hole, even at the outermost edges of the FOV. This reduction in dead space enables a system design that can get closer to anatomies and increase patient comfort.

A patient-centric detector design with 67 percent reduction in brain reach makes certain exams more tolerable. Normally, cardiac SPECT scans require patients to extend and hold their arms above their head for a long duration. With NM/CT 870 CZT, that scan time may be reduced by up to 75 percent²

and the near frameless detector design can enable patients to hold their arms at a more comfortable angle.

Conventional technology at 20 cm radius.

NM/CT 870 CZT at 14 cm radius.

PRODUCTIVITY

Switch to an all-digital workflow with SmartConsole

Introducing SmartConsole. It’s an all-new productivity hub for hybrid imaging. By automating SPECT/CT reconstruction, SmartConsole simplifies the workflow for complex hybrid and quantitative protocols and allows technologists to review results directly at the scanner console. It also allows physicians to review scans remotely from their own mobile devices. They can modify processing settings and initiate study processing anytime, anywhere across a LAN or a WAN*. That means better collaboration during scans and better accessibility for reviewing scans once complete.

SmartConsole enables a noticeable improvement in productivity. Now, a physician can provide their input remotely and digitally. For example, physicians can review a whole-body bone scan directly on their tablet or other mobile device and define the scan range limits they need from wherever they are. The time saved with this switch to a digital workflow helps make it possible to complete exams in predictable time slots.
*Minimum hardware and software requirements apply

SmartConsole makes advanced procedures more accessible by transferring exams directly to the PACS or other pre-defined DICOM destinations with no operator intervention, even if SPECT/CT fusion is not supported, by exporting the studies in DICOM PET format. Now, you can generate and send an additional dataset in PET DICOM format to enable quantitative SPECT results and SPECT SUV (Standard Uptake Value) on any PET DICOM compliant workstation or PACS. As a result, referring physicians can review and evaluate your SPECT/CT exams with the same quality of information they have come to expect from your PET/CT, as adjunct information to the original SPECT/CT images. All of which is part of our ongoing vision to grow and strengthen the role of nuclear medicine.

To lead clinical discovery with hybrid imaging, you need quantitation. It’s what makes it possible to not only find disease, but to follow its response to treatment over time. It helped establish PET/CT as a valuable clinical tool. Now, with recent advancements to technology, consistent and accurate quantitation is possible with SPECT/CT.

NM/CT 870 CZT is a SPECT/CT built for consistent, reproducible quantitation. The improvements to detector performance that you get with CZT enable exceptional spatial and energy resolution compared to Nal detectors. It also leverages CT-based attenuation and scatter correction along with Evolution⁵ image reconstruction. In addition, ever-increasing computational power enables precise camera calibration for less variation between exams.

Once your quantitative studies are acquired, the new SmartConsole, together with Xeleris, makes it easier to access them. With SmartConsole, your quantitative SPECT/CT studies are automatically transferred directly to the PACS or other pre-defined DICOM destinations. Furthermore, an additional dataset in PET DICOM format allows you to review and evaluate images on the same devices you use to view your PET/CT studies, as adjacent information to the original SPECT/CT images.

The Xeleris workstation is our Nuclear Medicine, PET, NM/CT and PET/CT processing, analysis and review system. It’s designed to leverage the latest in SPECT quantitative applications for routine clinical use, accelerate workflow and improve diagnostic confidence. It also opens the door to the new era of digital healthcare delivery through its potential to access the GE Health Cloud and with advanced applications to help solve some of the most complex clinical presentations.

Molecular imaging enables the search for a different kind of discovery. The kind that could have a lasting impact on the world. A true discovery. Not only is it proof of a new way to understand something hidden deep within us, it has the ability to transcend the individual to make a greater impact on all patients.

The search for true discovery is unique. It requires the right balance of technology and people. The technology to enable the search and the people to embrace it. We have worked with leaders in healthcare like you to understand what obstacles stand in your way and what solutions you seek.

NM/CT 870 CZT is the result of these partnerships. We hope you see it as we do. Not as another imaging product, but as a tool to help you bring your theories to life.